Pulmonary Lymphangiomatosis – insights into an ultra-rare disease

Résumé fourni par la source

Background: Pulmonary lymphangiomatosis (PL) is a very rare pulmonary disease with diffuse infiltration of the lung, pleura and/or mediastinum by abnormal lymphatics. Consented diagnostic or treatment approaches are not established. We therefore aimed to collect data on diagnostics and treatments in a cohort of patients with PL from a tertiary ILD center. Methods: Clinical, radiological and outcome data from PL patients were collected retrospectively. Results: 6 patients were diagnosed between 2007-2017. PL was diagnosed more commonly in female (83%), never smokers (67%) and younger patients (mean age 35 yrs). Main clinical symptoms comprised hem- and chyloptysis (50%) and dyspnea (33%). PFT was restrictive (mean VC 69%) with impaired DLCO (mean 68%). Radiological assessment showed mainly mediastinal involvement (100%), and pulmonary and/or pericardial effusions (50%), interstitial changes were rare (17%). Diagnosis was confirmed by surgical biopsy in all patients. 3 patients were treated with sirolimus, 1 combined with surgical intervention and radiotherapy and 2 received mediastinal surgical resections. Clinical and radiological improvement was demonstrated for all patients treated with sirolimus after a mean follow up of 20 months. 1 patient received lung transplant for disease progression. Survival rates were 83% after a mean follow up of 24 months. Conclusion: This case series illustrates the variability of the clinical presentation of PL. Treatment with Sirolimus may be a therapeutic option. However, further investigation is needed to understand the pathogenesis of lymphangiomatosis in order to establish therapeutic approaches.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.